Last reviewed · How we verify
Methylphenidate Oral Solution
Methylphenidate blocks the reuptake of dopamine and norepinephrine in the central nervous system, increasing their availability in the brain.
Methylphenidate blocks the reuptake of dopamine and norepinephrine in the central nervous system, increasing their availability at the synapse. Used for Attention-deficit/hyperactivity disorder (ADHD), Narcolepsy.
At a glance
| Generic name | Methylphenidate Oral Solution |
|---|---|
| Also known as | MPH, Ritalin, Concerta, Jornay PM, Biphentin® |
| Sponsor | University of California, Davis |
| Drug class | Sympathomimetic amine; CNS stimulant |
| Target | Dopamine transporter (DAT); Norepinephrine transporter (NET) |
| Modality | Small molecule |
| Therapeutic area | Neurology; Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Methylphenidate is a sympathomimetic amine that inhibits the reuptake transporters for dopamine and norepinephrine, leading to increased concentrations of these neurotransmitters in the synaptic cleft. This enhanced dopaminergic and noradrenergic signaling improves attention, focus, and impulse control. The oral solution formulation allows for flexible dosing and is particularly useful in pediatric populations or patients with difficulty swallowing tablets.
Approved indications
- Attention-deficit/hyperactivity disorder (ADHD)
- Narcolepsy
Common side effects
- Insomnia
- Decreased appetite
- Headache
- Nervousness or anxiety
- Abdominal pain
- Tachycardia
- Elevated blood pressure
Key clinical trials
- Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities (PHASE1)
- Cannabidiol and CES1 Interactions in Healthy Subjects (PHASE4)
- Treatment of Orthostatic Hypotension in Autonomic Failure (PHASE1)
- Quillivant Oral Suspension (Quillivant XR) in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Methylphenidate Oral Solution CI brief — competitive landscape report
- Methylphenidate Oral Solution updates RSS · CI watch RSS
- University of California, Davis portfolio CI